Multifunctional nanoparticle-EpCAM aptamer bioconjugates: A paradigm for targeted drug delivery and imaging in cancer therapy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 379-389

  Das, Manasi ^a   Duan, Wei ^b   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

EpCAM aptamer; Nanotheranostics; Nutlin 3a; PLGA NPs; Quantum dots

Indexed keywords

CELL DEATH; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; NANOCRYSTALS; NANOPARTICLES; ONCOLOGY; SEMICONDUCTOR QUANTUM DOTS;

APTAMERS; CANCER DIAGNOSTICS; CANCER THERAPY AND BIOIMAGING; CYTOTOXICITY ASSAYS; MULTI-FUNCTIONAL NANOPARTICLES; NANOTHERANOSTICS; NUTLIN-3A; POLY LACTIDE-CO-GLYCOLIDE;

TARGETED DRUG DELIVERY;

APTAMER; CASPASE 3; EPITHELIAL CELL ADHESION MOLECULE; NUTLIN 3; PROTEIN BCL 2; PROTEIN P53; QUANTUM DOT; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; LACTIC ACID; NANOPARTICLE; PIPERAZINE DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TUMOR ANTIGEN;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; DRUG DELIVERY SYSTEM; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; MONOLAYER CULTURE; TUMOR SPHEROID; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; FEMALE; PATHOLOGY;

ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMIDAZOLES; LACTIC ACID; NANOPARTICLES; PIPERAZINES; POLYGLYCOLIC ACID; QUANTUM DOTS;

EID: 84922779431     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.002     Document Type: Article

References (50)

1. Fang J., Sawa T., Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003, 519:29-49.
2. Das M., Mohanty C., Sahoo S.K. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 2009, 6:285-304.
3. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8:1112-1120.
4. Sahoo S.K., Ma W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004, 112:335-340.
5. Mohanty C., Sahoo S.K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31:6597-6611.
6. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010, 79:330-338.
7. Peng X.H., Qian X., Mao H., Wang A.Y., Chen Z.G., Nie S., et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008, 3:311-321.
8. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
9. Secchiero P., Bosco R., Celeghini C., Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011, 17:569-577.
10. Lau L.M., Nugent J.K., Zhao X., Irwin M.S. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008, 27:997-1003.
11. Endo S., Yamato K., Hirai S., Moriwaki T., Fukuda K., Suzuki H., et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci 2011, 102:605-613.
12. Lain S., Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer 2003, 39:1053-1060.
13. Shen H., Maki C.G. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des 2011, 17:560-568.
14. Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K., Fehse B., et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009, 69:416-421.
15. Voltan R., Secchiero P., Ruozi B., Caruso L., Forni F., Palomba M., et al. Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells. Curr Med Chem 2013, 20:2712-2722.
16. Voltan R., Secchiero P., Ruozi B., Forni F., Agostinis C., Caruso L., et al. Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts. Clin Cancer Res 2013, 19:3871-3880.
17. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
18. Panyam J., Sahoo S.K., Prabha S., Bargar T., Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d, l-lactide-co-glycolide) nanoparticles. Int J Pharm 2003, 262:1-11.
19. Das M., Dilnawaz F., Sahoo S.K. Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy. Nanomedicine (Lond) 2011, 6:489-507.
20. Phillips M.A., Gran M.L., Peppas N.A. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010, 5:143-159.
21. Hussain S., Pluckthun A., Allen T.M., Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 2007, 6:3019-3027.
22. Kanwar J.R., Roy K., Kanwar R.K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 2011, 46:459-477.
23. Munz M., Baeuerle P.A., Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69:5627-5629.
24. Simon M., Stefan N., Pluckthun A., Zangemeister-Wittke U. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin Drug Deliv 2013, 10:451-468.
25. Trzpis M., McLaughlin P.M., de Leij L.M., Harmsen M.C. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007, 171:386-395.
26. Savla R., Taratula O., Garbuzenko O., Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 2011, 153:16-22.
27. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N., Lavan D.A., Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004, 64:7668-7672.
28. Brody E.N., Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000, 74:5-13.
29. Bagalkot V., Zhang L., Levy-Nissenbaum E., Jon S., Kantoff P.W., Langer R., et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007, 7:3065-3070.
30. Nimjee S.M., Rusconi C.P., Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu Rev Med 2005, 56:555-583.
31. Li L., Xiang D., Shigdar S., Yang W., Li Q., Lin J., et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int J Nanomedicine 2014, 9:1083-1096.
32. Shigdar S., Lin J., Yu Y., Pastuovic M., Wei M., Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 2011, 102:991-998.
33. Shigdar S., Qian C., Lv L., Pu C., Li Y., Li L., et al. The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer. PLoS One 2013, 8:e57613.
34. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
35. Medintz I.L., Uyeda H.T., Goldman E.R., Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005, 4:435-446.
36. Nehilla B.J., Allen P.G., Desai T.A. Surfactant-free, drug-quantum-dot coloaded poly(lactide-co-glycolide) nanoparticles: towards multifunctional nanoparticles. ACS Nano 2008, 2:538-544.
37. Pan J., Feng S.S. Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials 2009, 30:1176-1183.
38. Wang A.Z., Bagalkot V., Vasilliou C.C., Gu F., Alexis F., Zhang L., et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3:1311-1315.
39. Kim M., Ock K., Cho K., Joo S.W., Lee S.Y. Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media. Chem Commun (Camb) 2012, 48:4205-4207.
40. Maaser K., Borlak J. A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators. Br J Cancer 2008, 99:1635-1643.
41. Robertson F.M., Ogasawara M.A., Ye Z., Chu K., Pickei R., Debeb B.G., et al. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen 2010, 15:820-829.
42. Bayles A.R., Chahal H.S., Chahal D.S., Goldbeck C.P., Cohen B.E., Helms B.A. Rapid cytosolic delivery of luminescent nanocrystals in live cells with endosome-disrupting polymer colloids. Nano Lett 2010, 10:4086-4092.
43. Kocbek P., Obermajer N., Cegnar M., Kos J., Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007, 120:18-26.
44. Muthu M.S., Leong D.T., Mei L., Feng S.S. Nanotheranostics-application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4:660-677.
45. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22:969-976.
46. Subramanian N., Raghunathan V., Kanwar J.R., Kanwar R.K., Elchuri S.V., Khetan V., et al. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis 2012, 18:2783-2795.
47. Sahoo S.K., Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2005, 2:373-383.
48. Reddy M.K., Vasir J.K., Sahoo S.K., Jain T.K., Yallapu M.M., Labhasetwar V. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv 2008, 1:209-216.
49. Shapiro G.I., Harper J.W. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 1999, 104:1645-1653.
50. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.